When countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue Reading

MOSAIC is a seven-year global project to accelerate introduction and scale-up of new biomedical prevention products and expedite their availability, acceptance, uptake, and impact in PEPFAR programs to help individuals, especially women, prevent HIV and other infectious diseases.
When countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue Reading
Today, we observe International Women’s Day, a day to celebrate the many achievements of women around the globe.
Continue Reading
In the MOSAIC project, the end user—that is, the people who need and/or want to use biomedical HIV prevention (PrEP) products—is at the center of all that we do.
Continue Reading
In this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.
Continue Reading
When I was a medical student in the early 1990s, the only drug we had to treat HIV was azidothymidine (AZT). I remember the excitement when combination therapy was developed; we all embraced a new acronym: HAART – highly active antiretroviral therapy.
Continue Reading
Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a five-year (2021-2026) global project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID). This blog platform, officially launched in January 2022, will feature curated content from the MOSAIC project, as well as relevant content from others working to expand access to a multi-product HIV prevention market.
Continue Reading